Article Text

Download PDFPDF
1079 Tolerability and the use of low-dose olaparib as maintenance therapy in Asian women with advanced primary epithelial ovarian cancer
  1. Hiu Mei Luk,
  2. Man Yee Chu and
  3. Ka Yu Tse
  1. Queen Mary Hospital, Hong Kong, Hong Kong SAR


Introduction/Background Patients with advanced epithelial ovarian cancer (EOC) have a poor prognosis. The Olaparib significantly prolonged their progression-free survival (PFS). However, its tolerability in Asian population and the role of low dose in real-world practice was not well-reported.

Methodology Patients with primary or recurrent EOC using Olaparib in February, 2019 – July, 2023 were recruited in this study. Their clinical characteristics, including side effects graded by the CTCAE 5.0 and survival data evaluated by Kaplan-Meier curves, were reviewed retrospectively.

Results 21 patients received Olaparib for advanced EOC. The median age was 60 years (range 37 – 75 years) and the median body weight was 53kg (range 38.0 - 83.4kg). All patients started with 300mg tablets BD, except two who started with 250mg tablets. 13 patients (61.9%) required drug interruption, which occurred as early as 1.5 months (range 0.7 – 9.5 months) after initiation of Olaparib. 14 patients (66.7%) required dose reduction occurring 1.8 months (range 0.8 – 9.9 months), and 9 (42.9%) required a second dose reduction to 200mg BD after a median of 3 months (range 1.4 – 12.5 months). Although not included in most studies, 6 patients (28.6%) reduced the dose to 150mg BD, where 2 was due to anemia, 2 due to thrombocytopenia and 2 due to elevated creatinine. Median PFS and overall survival were not reached yet, but patients with 150mg BD did not have a higher recurrence rate compared to patients using the standard dose (16.7% vs 13.3%; p = 0.658).

Conclusion Our population had a high drug interruption/dosage modification rate. Although it is usually recommended to terminate Olaparib if patients cannot tolerate 200mg BD, a lower dosage of 150mg BD may still show beneficial effects in our cohort. A longer follow-up period and a larger cohort are needed to prove the value of this dosage.

Disclosures I have no potential conflict of interest to report.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.